Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Core Insights - Silo Pharma, Inc. has received a Notice of Allowance from the Japan Patent Office for a patent application related to its lead asset, SPC-15, which targets Post-Traumatic Stress Disorder (PTSD) [1][2][3] - The patent application is titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," enhancing Silo's intellectual property portfolio in stress-modulating therapeutics [2][3] - The approval of the patent is significant for Silo as it protects its lead asset and reinforces the novelty of its approach to preventing stress-induced behavioral disorders [3] Company Overview - Silo Pharma is a developmental-stage biopharmaceutical company focused on innovative formulations and drug delivery systems for traditional therapeutics and psychedelic treatments [1][4] - The company addresses underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, with a portfolio that includes SPC-15 for PTSD and SP-26 for fibromyalgia and chronic pain [4] - Silo conducts research in collaboration with leading universities and laboratories, indicating a strong foundation for its therapeutic developments [4]